-
6 billion! The U.S. interest in another domestically produced PD-1 was sold
Time of Update: 2023-01-05
The maximum total transaction amount is about 6 billion RMBSlightly different from the common drug authorization transaction, this transaction sets up a VAM repurchase clause:After the third anniversary of Fosun Pharma's first commercial sale of slilumab, Henlius has the right to repurchase the relevant license rights for a consideration of three times the sales amount in the past one year, with a minimum of US$250 million.
-
Domestic and foreign pharmaceutical companies are achieving "win-win" through cooperation
Time of Update: 2022-12-30
On December 16, Zhejiang Daoer Biotechnology Co. , Ltd. announced that it has reached a clinical trial cooperation agreement with Merck to explore the clinical trial of Doyle Biologics anti-Claudin18
-
The research team of Wei Rui/Hong Tianpei of the Third Hospital of Peking University published the research results of the regeneration mechanism of islet β cells online in Diabetologia
Time of Update: 2022-11-26
The Wei Rui/Hong Tianpei research team first reported in iScience in 2019 that glucagon receptor (GCGR) monoclonal antibody (mAb) blocking glucagon signaling can induce transdifferentiation of islet α cells to β cells in mice with type 1 diabetes with absolute deficiency of β cells, thereby promoting β cell regeneration.
-
Letter on the Public Solicitation of Opinions on the Guiding Principles for the Naming of Generic Names of Chemical Drugs
Time of Update: 2022-10-12
xlsx In order to do a good job in the naming of generic names of chemical drugs, our committee has organized the drafting of the "Guiding Principles for the Naming of Common Names of Chemical Drugs (Draft for Solicitation of Comments)" (see Annex 1), which is now open to the public for comments.
-
The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use
Time of Update: 2022-10-06
BEIJING, Aug. 24, 2022 /PRNewswire/ -- Nuocheng Jianhua and Connoya jointly announced today that they have received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration The CCR8-targeting monoclonal antibody CM369 developed by Nuojiancheng has carried out clinical trials in advanced solid tumors .
-
ARD: Incidence and risk of serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors
Time of Update: 2022-04-18
Although the results need to be interpreted with caution given the many important differences between the RA and PsA populations, the findings suggest that clinicians should consider a diagnosis of rheumatism when initiating TNFi therapy and assessing a patient's risk for future serious infections .
-
Express second-line treatment of liver cancer, Keytruda combination achieves the primary endpoint of Phase 3 clinical trials
Time of Update: 2022-02-22
(MSD) recently announced that its anti-PD-1 therapy Keytruda, in combination with best supportive care (BSC), has been used in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib in Asia.
com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/ Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research .
-
mRNA cancer vaccine obtains FDA fast track qualification to treat melanoma
Time of Update: 2021-12-01
“The FDA’s grant of Fast Track status underscores the potential of our FixVac platform, which is expected to solve the current treatment challenges faced by melanoma patients .
"Reference materials:Reference materials:[1] BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma.
Retrieved November 19, 2021, from https:// /BioNTech-Receives-FDA-Fast-Track-Designation-for-its-FixVac-Candidate-BNT111-in-Advanced-Melanoma.
-
What happened after the two HIV-infected patients stopped treatment
Time of Update: 2021-11-15
Researchers say that a deep understanding of the mechanisms by which certain HIV-infected individuals spontaneously control viral replication will help develop new treatment strategies to achieve sustained viral suppression without the need for antiretroviral therapy .
-
Focus on drug targets: PD-1 / PD-L1, when will the internal volume be closed
Time of Update: 2021-11-01
Its approval is based on a key global Phase III clinical study called CheckMate-649, which aims to evaluate its combined chemotherapy versus chemotherapy alone for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma as the first-line treatment Efficacy and safety in the global population (including Chinese patients) .
-
Boehringer Ingelheim and Anritsu Xirong jointly developed EI-001 and completed clinical application
Time of Update: 2021-09-04
EI-001 antibodies are prepared by a single human B cells obtained technology, which is closely related to target the pathology of vitiligo, hepatitis B and the like .
-
The U.S. will propose two bills to reduce dependence on China’s pharmaceutical industry and enhance U.S. manufacturing capabilities
Time of Update: 2021-08-29
S. Senate and a proposal in the House of Representatives both propose to relocate the pharmaceutical industry from China to the United States through cooperation with American universities to train labor and develop manufacturing technologies .
-
JNNP: Multiple Sclerosis: Structural and functional integrity of the visual system after alemtuzumab treatment
Time of Update: 2021-08-03
Although the powerful anti-inflammatory effects of alemtuzumab may partly explain the early clinical improvement, the long-term benefits and continued normalization of brain atrophy rate increase the possibility of neuroprotective mode of action, and have a positive impact on recovery including remyelination.
-
Daiichi Sankyo's HER3 ADC is approved for the treatment of non-small cell lung cancer
Time of Update: 2021-08-01
On July 13, the CDE official website showed that Daiichi Sankyo's new HER3 ADC drug U3-1402 was approved for clinical use and is intended to be used for non-small cell lung cancer .
U3-1402 is an antibody-conjugated drug under development by Daiichi Sankyo .
-
The initial application, the strength is full: the superior curative effect of Disumab, helps the sustained benefit of lung cancer bone metastasis
Time of Update: 2021-06-04
In the treatment of bone metastases, the patient's blood calcium, blood phosphorus, and alkaline phosphatase returned to normal after 1 month of treatment with desulumab, and the bone destruction was significantly improved after 2 cycles, and the pain score was also reduced from 7 to 2 , The pain symptoms disappeared after 6 months of treatment, and there was no obvious abnormality in the vertebral body radioactivity distribution after 8 cycles.
